β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK

Quentin Q. Li, Rebecca X. Lee, Huasheng Liang, Gangduo Wang, Jueli M. Li, Yuhua Zhong, Eddie Reed

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

β-Elemene is a promising new plant-derived drug with broad-spectrum anticancer activity. It also increases cisplatin cytotoxicity and enhances cisplatin sensitivity in resistant human carcinoma cells. However, little is known about the mechanism of its action. To explore the potential therapeutic application of β-elemene as a drug-resistance modulator, this study investigated the underlying mechanism of β-elemene activity in cisplatin-resistant ovarian cancer cells. β-Elemene enhanced cisplatin sensitivity to a much greater extent in chemoresistant A2780/CP70 and MCAS human ovarian carcinoma cells compared to the chemosensitive parental cell line A2780. The dose-modifying factors for cisplatin were between 35 and 60 for A2780/CP70 cells and between 1.6 and 2.5 for A2780 cells. In the cisplatin-resistant ovarian carcinoma cells, β-elemene abrogated cisplatin-induced expression of excision repair cross-complementation group-1 (ERCC-1), a marker gene in the nucleotide excision repair pathway that repairs cisplatin-caused DNA damage. In addition, β-elemene not only reduced the level of X-linked inhibitor of apoptosis protein (XIAP), but also downregulated cisplatin-mediated XIAP expression in chemoresistant cells. Furthermore, β-elemene blocked the cisplatin-stimulated increase in the level of phosphorylated c-Jun NH2-terminal kinase (JNK) in these cells. These novel findings suggest that the β-elemene enhancement of cisplatin sensitivity in human chemoresistant ovarian cancer cells is mediated at least in part through the impairment of DNA repair activity and the activation of apoptotic signaling pathways, thereby making resistant ovarian cancer cells susceptible to cisplatin-induced cell death.

Original languageEnglish (US)
Pages (from-to)721-728
Number of pages8
JournalInternational Journal of Oncology
Volume43
Issue number3
DOIs
StatePublished - Sep 2013
Externally publishedYes

Fingerprint

X-Linked Inhibitor of Apoptosis Protein
JNK Mitogen-Activated Protein Kinases
DNA Repair
Cisplatin
Down-Regulation
Carcinoma
Ovarian Neoplasms
elemene
Drug Resistance
DNA Damage

Keywords

  • β-elemene
  • Apoptosis
  • C-Jun NH-terminal kinase
  • Chinese medicine
  • Cisplatin resistance
  • Excision repair cross-complementation group-1
  • Ovarian cancer
  • X-linked inhibitor of apoptosis protein

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK. / Li, Quentin Q.; Lee, Rebecca X.; Liang, Huasheng; Wang, Gangduo; Li, Jueli M.; Zhong, Yuhua; Reed, Eddie.

In: International Journal of Oncology, Vol. 43, No. 3, 09.2013, p. 721-728.

Research output: Contribution to journalArticle

Li, Quentin Q. ; Lee, Rebecca X. ; Liang, Huasheng ; Wang, Gangduo ; Li, Jueli M. ; Zhong, Yuhua ; Reed, Eddie. / β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK. In: International Journal of Oncology. 2013 ; Vol. 43, No. 3. pp. 721-728.
@article{8f19c3f15bac4c3690bfe7a0bd30b92b,
title = "β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK",
abstract = "β-Elemene is a promising new plant-derived drug with broad-spectrum anticancer activity. It also increases cisplatin cytotoxicity and enhances cisplatin sensitivity in resistant human carcinoma cells. However, little is known about the mechanism of its action. To explore the potential therapeutic application of β-elemene as a drug-resistance modulator, this study investigated the underlying mechanism of β-elemene activity in cisplatin-resistant ovarian cancer cells. β-Elemene enhanced cisplatin sensitivity to a much greater extent in chemoresistant A2780/CP70 and MCAS human ovarian carcinoma cells compared to the chemosensitive parental cell line A2780. The dose-modifying factors for cisplatin were between 35 and 60 for A2780/CP70 cells and between 1.6 and 2.5 for A2780 cells. In the cisplatin-resistant ovarian carcinoma cells, β-elemene abrogated cisplatin-induced expression of excision repair cross-complementation group-1 (ERCC-1), a marker gene in the nucleotide excision repair pathway that repairs cisplatin-caused DNA damage. In addition, β-elemene not only reduced the level of X-linked inhibitor of apoptosis protein (XIAP), but also downregulated cisplatin-mediated XIAP expression in chemoresistant cells. Furthermore, β-elemene blocked the cisplatin-stimulated increase in the level of phosphorylated c-Jun NH2-terminal kinase (JNK) in these cells. These novel findings suggest that the β-elemene enhancement of cisplatin sensitivity in human chemoresistant ovarian cancer cells is mediated at least in part through the impairment of DNA repair activity and the activation of apoptotic signaling pathways, thereby making resistant ovarian cancer cells susceptible to cisplatin-induced cell death.",
keywords = "β-elemene, Apoptosis, C-Jun NH-terminal kinase, Chinese medicine, Cisplatin resistance, Excision repair cross-complementation group-1, Ovarian cancer, X-linked inhibitor of apoptosis protein",
author = "Li, {Quentin Q.} and Lee, {Rebecca X.} and Huasheng Liang and Gangduo Wang and Li, {Jueli M.} and Yuhua Zhong and Eddie Reed",
year = "2013",
month = "9",
doi = "10.3892/ijo.2013.1996",
language = "English (US)",
volume = "43",
pages = "721--728",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK

AU - Li, Quentin Q.

AU - Lee, Rebecca X.

AU - Liang, Huasheng

AU - Wang, Gangduo

AU - Li, Jueli M.

AU - Zhong, Yuhua

AU - Reed, Eddie

PY - 2013/9

Y1 - 2013/9

N2 - β-Elemene is a promising new plant-derived drug with broad-spectrum anticancer activity. It also increases cisplatin cytotoxicity and enhances cisplatin sensitivity in resistant human carcinoma cells. However, little is known about the mechanism of its action. To explore the potential therapeutic application of β-elemene as a drug-resistance modulator, this study investigated the underlying mechanism of β-elemene activity in cisplatin-resistant ovarian cancer cells. β-Elemene enhanced cisplatin sensitivity to a much greater extent in chemoresistant A2780/CP70 and MCAS human ovarian carcinoma cells compared to the chemosensitive parental cell line A2780. The dose-modifying factors for cisplatin were between 35 and 60 for A2780/CP70 cells and between 1.6 and 2.5 for A2780 cells. In the cisplatin-resistant ovarian carcinoma cells, β-elemene abrogated cisplatin-induced expression of excision repair cross-complementation group-1 (ERCC-1), a marker gene in the nucleotide excision repair pathway that repairs cisplatin-caused DNA damage. In addition, β-elemene not only reduced the level of X-linked inhibitor of apoptosis protein (XIAP), but also downregulated cisplatin-mediated XIAP expression in chemoresistant cells. Furthermore, β-elemene blocked the cisplatin-stimulated increase in the level of phosphorylated c-Jun NH2-terminal kinase (JNK) in these cells. These novel findings suggest that the β-elemene enhancement of cisplatin sensitivity in human chemoresistant ovarian cancer cells is mediated at least in part through the impairment of DNA repair activity and the activation of apoptotic signaling pathways, thereby making resistant ovarian cancer cells susceptible to cisplatin-induced cell death.

AB - β-Elemene is a promising new plant-derived drug with broad-spectrum anticancer activity. It also increases cisplatin cytotoxicity and enhances cisplatin sensitivity in resistant human carcinoma cells. However, little is known about the mechanism of its action. To explore the potential therapeutic application of β-elemene as a drug-resistance modulator, this study investigated the underlying mechanism of β-elemene activity in cisplatin-resistant ovarian cancer cells. β-Elemene enhanced cisplatin sensitivity to a much greater extent in chemoresistant A2780/CP70 and MCAS human ovarian carcinoma cells compared to the chemosensitive parental cell line A2780. The dose-modifying factors for cisplatin were between 35 and 60 for A2780/CP70 cells and between 1.6 and 2.5 for A2780 cells. In the cisplatin-resistant ovarian carcinoma cells, β-elemene abrogated cisplatin-induced expression of excision repair cross-complementation group-1 (ERCC-1), a marker gene in the nucleotide excision repair pathway that repairs cisplatin-caused DNA damage. In addition, β-elemene not only reduced the level of X-linked inhibitor of apoptosis protein (XIAP), but also downregulated cisplatin-mediated XIAP expression in chemoresistant cells. Furthermore, β-elemene blocked the cisplatin-stimulated increase in the level of phosphorylated c-Jun NH2-terminal kinase (JNK) in these cells. These novel findings suggest that the β-elemene enhancement of cisplatin sensitivity in human chemoresistant ovarian cancer cells is mediated at least in part through the impairment of DNA repair activity and the activation of apoptotic signaling pathways, thereby making resistant ovarian cancer cells susceptible to cisplatin-induced cell death.

KW - β-elemene

KW - Apoptosis

KW - C-Jun NH-terminal kinase

KW - Chinese medicine

KW - Cisplatin resistance

KW - Excision repair cross-complementation group-1

KW - Ovarian cancer

KW - X-linked inhibitor of apoptosis protein

UR - http://www.scopus.com/inward/record.url?scp=84880596859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880596859&partnerID=8YFLogxK

U2 - 10.3892/ijo.2013.1996

DO - 10.3892/ijo.2013.1996

M3 - Article

VL - 43

SP - 721

EP - 728

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 3

ER -